Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | POLB | P06746 | 3/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5532301 | 0.98 | KMT2A (0.39) | CA1CA2CA4KMT2AKDM4E | |
| SCHEMBL5534478 | 0.95 | PTGS1 (0.34) | CA1CA2CA4KMT2AKDM4E | |
| SCHEMBL5540002 | 0.88 | KDM4E (0.30) | KDM4EHSD17B10 | |
| SCHEMBL944400 | 0.74 | CA1 (0.32) | CA1CA2CA4KMT2A | |
| SCHEMBL944513 | 0.73 | THRB (0.35) | KMT2AKDM4EPOLBLMNACYP2D6 | |
| SCHEMBL6908002 | 0.71 | CA1 (0.45) | CA1CA2CA4KMT2AKDM4E | |
| SCHEMBL942827 | 0.69 | THRB (0.40) | KMT2AMAPT | |
| SCHEMBL941199 | 0.68 | THRB (0.32) | — | |
| SCHEMBL181970 | 0.68 | — | — | |
| SCHEMBL1568359 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070055081-A1 | Processes for production of alpha-aminooxyketones and alpha-hydroxyketones | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2007-03-08 | — | — | US | disclosed |
| EP-1717221-A1 | PROCESSES FOR PRODUCTION OF ALPHA-AMINOOXYKETONES AND ALPHA-HYDROXYKETONES | Japan Science and Technology Agency (JP) | 2006-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070055081-A1 | Processes for production of alpha-aminooxyketones and alpha-hydroxyketones | KHK, HCCS, XDH | CA1 3230/4885CA2 3909/4885CA4 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.